Perrigo Company PLC
NYSE:PRGO

  • LAST PRICE
    29.8300
  • TODAY'S CHANGE (%)
    -0.2700 (-0.8970%)
  • Bid / Lots
    29.9000/ 1
  • Ask / Lots
    31.0200/ 1
  • Open / Previous Close
    30.1400 / 30.1000
  • Day Range
    29.8200
    30.3500
  • 52 Week Range
    25.7700
    40.2800
  • Volume
    1,273,145

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • May 7, 2024

      Show headlines and story abstract

    • 8:28AM ET on Tuesday May 07, 2024 by MT Newswires
      Companies Mentioned: PRGO
      08:28 AM EDT, 05/07/2024 (MT Newswires) -- Perrigo (PRGO) reported Q1 adjusted earnings Tuesday of $0.29 per diluted share, down from $0.45 a year earlier. Three analysts surveyed by Capital IQ expected $0.23. Net sales for the quarter ended March ...

    • 6:42AM ET on Tuesday May 07, 2024 by MT Newswires
      Companies Mentioned: PRGO
      06:42 AM EDT, 05/07/2024 (MT Newswires) -- ...

    • 6:42AM ET on Tuesday May 07, 2024 by MT Newswires
      Companies Mentioned: PRGO
      06:42 AM EDT, 05/07/2024 (MT Newswires) -- ...

    • 6:31AM ET on Tuesday May 07, 2024 by Dow Jones
      Companies Mentioned: PRGO

      Primary CSCI First Quarter Category Drivers:
      -- Skin Care: Net sales of $115 million increased 37.5%, or 41.0% excluding the impact of currency, due to strong growth in Compeed driven by the new product launch of Compeed Spots and the absence of prior year distribution transitions. Category growth was also driven by performance of ACO and Sebamed, partially offset by a 2.2 percentage point reduction from exited product lines. -- Upper Respiratory: Net sales of $69 million decreased 18.5%, or 20.2% excluding the impact of currency, due primarily to lower net sales of cough cold products stemming from lower incidence of cough cold throughout the E.U. compared to the prior year and supply constraints on several products in the category. The category was also impacted by a 2.4 percentage points reduction from exited product lines. -- Healthy Lifestyle: Net sales of $65 million decreased 2.7%, or an increase of 4.7% excluding the impact of currency, due primarily to the seasonal sell in of anti-parasite products including Jungle Formula and Paranix, partially offset by lower category consumption in weight loss, impacting XLS Medical. The category was impacted by a 1.3 percentage points reduction from exited product lines. -- Pain & Sleep-Aids: Net sales of $51 million increased 3.0%, or a decrease of 0.9% excluding the impact of currency, due primarily to lower net sales of store brand products. -- VMS: Net sales of $45 million decreased 6.7%, or 7.8% excluding the impact of currency, due primarily to timing of sales of Granufink and Abte, in addition to promotional phasing of Davitamon. -- Women's Health: Net sales of $32 million increased 10.1%, or 9.9% excluding the impact of currency, due primarily to higher net sales of contraceptive products including EllaOne, driven by the absence of prior year distribution transitions. -- Oral Care: Net sales of $29 million decreased 1.5%, or 3.5% excluding the impact of currency, due primarily to lower net sales of store brand offerings. -- Digestive Health and Other: Net sales of $33 million increased 18.9%, or 17.9% excluding the impact of currency, due primarily to higher net sales of store brand digestive health products. TABLE VII PERRIGO COMPANY PLC RECONCILIATION OF NON-GAAP MEASURES CONSOLIDATED AND SELECTED SEGMENT INFORMATION (in millions, except per share amounts) (unaudited) Three Months Ended Consolidated Continuing March 30, April 1, Operations 2024 2023 Total Change Adjusted gross profit $ 395.5 $ 442.8 $ (47.4) (10.7) % Adjusted gross margin 36.5 % 37.5 % (90) bps Adjusted operating income $ 93.0 $ 119.6 $ (26.6) Adjusted operating margin 8.6 % 10.1 % (150) bps Consumer Self-Care International Adjusted gross profit $ 232.3 $ 228.2 $ 4.1 Adjusted gross margin 53.0 % 54.6 % (150) bps Adjusted operating income $ 86.1 $ 70.3 $ 15.8 22.5 % Adjusted operating margin 19.7 % 16.8 % 290 bps Consumer Self-Care Americas Adjusted gross profit $ 163.2 $ 214.7 $ (51.5) Adjusted gross margin 25.3 % 28.1 % (280) bps Adjusted operating income $ 52.7 $ 99.2 $ (46.5) (46.9) % Adjusted operating margin 8.2 % 13.0 % (480) bps Note: amounts may not add or recalculate due to rounding. Percentages are based on actuals.

    • 6:31AM ET on Tuesday May 07, 2024 by Dow Jones
      Companies Mentioned: PRGO

Peers Headlines